These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15855014)

  • 1. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
    Pinto LA; Castle PE; Roden RB; Harro CD; Lowy DR; Schiller JT; Wallace D; Williams M; Kopp W; Frazer IH; Berzofsky JA; Hildesheim A
    Vaccine; 2005 May; 23(27):3555-64. PubMed ID: 15855014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
    García-Piñeres A; Hildesheim A; Dodd L; Kemp TJ; Williams M; Harro C; Lowy DR; Schiller JT; Pinto LA
    Clin Vaccine Immunol; 2007 Aug; 14(8):984-9. PubMed ID: 17596432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
    Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.
    García-Piñeres AJ; Hildesheim A; Dodd L; Kemp TJ; Yang J; Fullmer B; Harro C; Lowy DR; Lempicki RA; Pinto LA
    J Immunol; 2009 Feb; 182(3):1706-29. PubMed ID: 19155521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
    Emeny RT; Wheeler CM; Jansen KU; Hunt WC; Fu TM; Smith JF; MacMullen S; Esser MT; Paliard X
    J Virol; 2002 Aug; 76(15):7832-42. PubMed ID: 12097595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
    Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
    Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
    Lenz P; Lowy DR; Schiller JT
    Eur J Immunol; 2005 May; 35(5):1548-56. PubMed ID: 15832296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
    Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
    J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV.
    Passmore JA; Burch VC; Shephard EG; Marais DJ; Allan B; Kay P; Rose RC; Williamson AL
    J Med Virol; 2002 Jun; 67(2):234-40. PubMed ID: 11992584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine.
    Negahdaripour M; Nezafat N; Heidari R; Erfani N; Hajighahramani N; Ghoshoon MB; Shoolian E; Rahbar MR; Najafipour S; Dehshahri A; Morowvat MH; Ghasemi Y
    Curr Pharm Biotechnol; 2020; 21(4):316-324. PubMed ID: 31729940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
    Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
    Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques.
    Tobery TW; Smith JF; Kuklin N; Skulsky D; Ackerson C; Huang L; Chen L; Cook JC; McClements WL; Jansen KU
    Vaccine; 2003 Mar; 21(13-14):1539-47. PubMed ID: 12615451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.